[Anti- tuberculosis treatment evaluation in northern districts of Buenos Aires suburbs].
The aim of this study was to analyze the epidemiologic impact produced by Direct Observed Treatment Strategy (DOTS) application regarding to its success in the 51h Sanitary Region during the year 2 003. The cure was evaluated by a cohort study comparing two groups. Group 1: Districts in which DOTS were applied in 65% or more TB patients; group 2: Districts applying DOTS in 64% or less, or without its implementation. The global mortality was analyzed on HIV (-) as well as on HIV (+) patients in both groups. In Municipalities where DOTS strategy was applied in >65% of notified cases, the treatment success was 85.7%; the cure rate of bacteriological confirmed pulmonary disease was 86.2% and non-adherence was proved in 8.8% of cases. When DOTS was applied in equal or less than 64% of the cases, the global cure reached 67.6%; in confirmed pulmonary disease it was 68.1%, and non-adherence was proved in 21.8% of cases. Global mortality due to TB was 5.2%; 22.3% in HIV (+) and 4.1% in HIV (-). While In group 1, the cure rate of co-infected TB/HIV patients was 55.2%, non-adherence was 6.9%, in group 2 these figures were 46.4% and 19.7% respectively. Mortality rate in HIV (+) patients was 31.0% in group 1, and 16.1% in group 2. These results show that DOTS application proved to be an efficient tool to cure most of the patients, reaching the proposed goal of 85%, therefore reducing the risk of illness in the community.
Chirico
Cristina
C
Programa de Control de la Tuberculosis de la Región Sanitaria V, Hospital Dr. A. A. Cetrángolo, Vicente López, Provincia de Buenos Aires. mchirino@intramed.net.ar
Kuriger
Adriana
A
Etchevarria
Mirta
M
Casamajor
Lujan
L
Morcillo
Nora
N
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001118:Argentina / Q000453:epidemiology; D015331:Cohort Studies; D023801:Directly Observed Therapy / Q000592:standards*; D015658:HIV Infections / Q000382:microbiology*; D006801:Humans; D016079:Refusal to Treat; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control
D000995:Antitubercular Agents